Since Arvinas Inc. (NASDAQ:ARVN) and Cocrystal Pharma Inc. (NASDAQ:COCP) are part of the Biotechnology industry, they are influenced by compare. The influences particularly affect the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership of both companies.
Valuation & Earnings
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Cocrystal Pharma Inc.||3||14.28||N/A||-1.49||0.00|
Table 1 demonstrates Arvinas Inc. and Cocrystal Pharma Inc.’s top-line revenue, earnings per share (EPS) and valuation.
Table 2 represents Arvinas Inc. (NASDAQ:ARVN) and Cocrystal Pharma Inc. (NASDAQ:COCP)’s return on assets, return on equity and net margins.
|Net Margins||Return on Equity||Return on Assets|
|Cocrystal Pharma Inc.||0.00%||-48.9%||-45%|
The Current Ratio and Quick Ratio of Arvinas Inc. are 8.7 and 8.7 respectively. Its competitor Cocrystal Pharma Inc.’s Current Ratio is 5.6 and its Quick Ratio is 5.6. Arvinas Inc. can pay off short and long-term obligations better than Cocrystal Pharma Inc.
In next table is delivered Arvinas Inc. and Cocrystal Pharma Inc.’s ratings and recommendations.
|Sell Ratings||Hold Ratings||Buy Ratings||Rating Score|
|Cocrystal Pharma Inc.||0||0||0||0.00|
Arvinas Inc. has a consensus price target of $31.5, and a 29.05% upside potential.
Insider and Institutional Ownership
The shares of both Arvinas Inc. and Cocrystal Pharma Inc. are owned by institutional investors at 71.1% and 12.8% respectively. Arvinas Inc.’s share held by insiders are 0.4%. On the other hand, insiders held about 64.15% of Cocrystal Pharma Inc.’s shares.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Cocrystal Pharma Inc.||7.2%||5.07%||-11.63%||-20.56%||-46.48%||-36.67%|
For the past year Arvinas Inc. had bullish trend while Cocrystal Pharma Inc. had bearish trend.
Arvinas Inc. beats Cocrystal Pharma Inc. on 6 of the 8 factors.
Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.
Cocrystal Pharma, Inc., a preclinical-stage biopharmaceutical company, focuses on developing antiviral therapeutics for human diseases. The company focuses on developing inhibitors that target viral replication enzymes and viral replication protein. It is developing antiviral therapeutics for human diseases, including hepatitis C virus (HCV), influenza virus, and norovirus. The company also develops targeted in-house chemical libraries consisting of nucleosides, non-nucleoside inhibitors, metal-binding inhibitors, and fragments. It has research collaboration agreement with HitGen, Ltd. and InterX, Inc. to develop small molecule drug candidates against several undisclosed targets. Cocrystal Pharma, Inc. was founded in 2007 and is headquartered in Tucker, Georgia.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.